Clinical Guide Balances GLP-1 RA Benefits and Risks for Shared Decision-Making in Expanded Use

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has rapidly expanded beyond traditional management of type 2 diabetes and obesity into a growing range of metabolic and cardiorenal indications. This shift has led to their adoption by younger adults and lower-risk populations seeking preventive or quality-of-life benefits, moving beyond therapeutic necessity to elective health optimization. Clinicians now face significant challenges in patient selection, monitoring, and counseling, especially with the rise of telemedicine and commercial weight management programs, highlighting a critical need for standardized clinical guidance.

This review synthesizes current evidence to provide a concise, patient-oriented framework for shared decision-making concerning GLP-1 receptor agonists. The authors aimed to equip clinicians with a practical guide by summarizing key physiological mechanisms and clinical benefits of these agents. They also outlined strategies for managing adverse events, effectively counseling patients, and reducing the stigma often associated with GLP-1 RA use. The framework integrates both randomized trial data and real-world practice insights to address contemporary clinical challenges.

The review provides a structured approach for clinicians to navigate the expanded landscape of GLP-1 RA prescribing. It details the key physiological mechanisms through which GLP-1 RAs exert their effects, alongside a comprehensive summary of their established clinical benefits across various indications. The guide offers practical strategies for identifying and managing common adverse events, ensuring patient safety and adherence. Furthermore, it includes specific recommendations for patient counseling, focusing on setting realistic expectations and fostering informed consent. The authors also address the crucial aspect of reducing stigma associated with GLP-1 RA therapy, promoting better patient engagement and outcomes. This framework is designed to support individualized treatment strategies.

The guide aims to equip clinicians with a practical framework for individualized treatment strategies and risk mitigation in the expanding landscape of GLP-1 RA use.